Dear User, This website provides you with information only for healthcare professionals. According to the drug promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have full access to our website. To visit our page please login.

Daiichi Sankyo
Doc Check

European News

Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation

Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio

Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation

Daiichi Sankyo Cancer Enterprise Showcases New Data on Multiple Compounds at American Association for Cancer Research 2017 Annual Meeting

New analysis demonstrates that insulin-requiring diabetes increases the risk of stroke or systemic embolism in patients with atrial fibrillation

Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA®▼ (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE

Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily LIXIANA®▼ (edoxaban) in Patients with Non-valvular Atrial Fibrillation to be Presented at AHA Scientific Sessions 2016

World Stroke Day 2016: Research reveals delayed diagnosis leaves atrial fibrillation patients at major stroke risk

Daiichi Sankyo announces new data to be presented at the ISPOR EU Congress 2016 analysing the safety, efficacy and cost-effectiveness of LIXIANA®▼ (edoxaban)

Daiichi Sankyo Announces First Patient Enrolled in Phase 3 QuANTUM-First Trial Investigating Quizartinib in Newly-Diagnosed FLT3-ITD+ Acute Myeloid Leukemia

Global News

Global LIXIANA® Press Portal

Cookie preferences tool